Chemical Structure : DALTAC-1
CAS No.:
DALTAC-1
(JYZ3032, Domain-ALTeration Chimera 1)
Catalog No.: PC-26742Not For Human Use, Lab Use Only.
DALTAC-1 (JYZ3032, Domain-ALTeration Chimera 1) is a specific AR-p300/CBP Domain-ALTeration Chimeras (DALTAC), targets the AR-p300 complex by repurposing their natural interfaces to block activation of the AR oncogenic enhanceosome, selectively suppresses the growth of AR-positive prostate cancer cells.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Purity & Documentation Purity:
>98% (HPLC)
Biological Activity
DALTAC-1 (JYZ3032, Domain-ALTeration Chimera 1) is a specific AR-p300/CBP Domain-ALTeration Chimera (DALTAC), targets the AR-p300 complex by repurposing their natural interfaces to block activation of the AR oncogenic enhanceosome, selectively suppresses the growth of AR-positive prostate cancer cells.
DALTAC-1 induces AR and p300 proteins into proximity to form a stable ternary complex.
DALTAC-1-induced proximity of AR and p300 proteins inhibits their oncogenic transcriptional output in AR-positive prostate cancer cells.
DALTAC-1 selectively reprograms the acetylome in AR-positive prostate cancer cells.
DALTAC-1 potently suppresses the growth of prostate cancer organoids, exhibits potent in vivo efficacy against prostate cancer.
DALTAC-1 effectively redirects AR-p300 interactions, inhibiting p300 binding to the AR-NTD while enhancing its interaction with the AR-LBD.
Physicochemical Properties
|
M.Wt
|
974.60
|
|
Formula
|
C52H62ClF2N13O2
|
|
Appearance
|
Solid
|
|
CAS No.
|
|
|
Storage
|
- Solide Powder
-
-20°C 12 Months; 4°C 6 Months
|
- In Solvent
-
-80°C 6 Months; -20°C 6 Months
|
|
Shipping
|
|
|
Solubility
|
10 mM in DMSO
|
|
Chemical Name/SMILES
|
6-(4-(((1r,4r)-4-(5-acetyl-3-(7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)cyclohexyl)methyl)piperazin-1-yl)-N-((1r,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohexyl)pyridazine-3-carboxamide
|
References
1. Luo J, et al. bioRxiv [Preprint]. 2026 Apr 28:2026.04.24.720638.
Contact Us
sales@probechem.com
